Ideaya Biosciences Enrolls First Patient in IDE892 Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy IDYA?
Ideaya Biosciences announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an investigational MTA-cooperative PRMT5 inhibitor being developed for patients with MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE892 as a monotherapy agent and in combination with IDE397, Ideaya's MAT2A inhibitor, in mid-2026. Dual inhibition of IDE892 and IDE397 has demonstrated durable and well-tolerated tumor regressions in preclinical MTAP-deleted tumor models, including in NSCLC.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 32.830
Low
30.00
Averages
49.86
High
79.00
Current: 32.830
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEAYA Initiates Phase 1 Trial for IDE892
- Trial Commencement: IDEAYA Biosciences has announced the enrollment of the first patient in its Phase 1 clinical trial for IDE892, a potential best-in-class PRMT5 inhibitor targeting MTAP-deleted solid tumors, highlighting the company's leadership in precision oncology.
- Drug Properties Advantage: IDE892 exhibits approximately 1,400-fold selective binding to MTA-PRMT5 complexes and demonstrates single-digit nanomolar potency in MTAP-deleted cell lines, indicating its potential to significantly enhance clinical outcomes for patients.
- Combination Therapy Potential: The combination with IDE397 has shown durable tumor regressions in preclinical models, suggesting that dual inhibition strategies may provide new treatment options for patients with MTAP-deleted tumors, addressing the urgent market need for effective therapies.
- Strategic Priority Shift: IDEAYA is deprioritizing clinical combination activities with Trodelvy to focus on advancing its MTAP-deleted pipeline, demonstrating the company's strong commitment to precision therapies and aiming to capture future market opportunities.
See More
Biocytogen and IDEAYA Advance New Drug Clinical Trial
- Trial Initiation: IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, aimed at evaluating the drug's safety, tolerability, and pharmacokinetics, marking a significant step in the clinical evaluation of this bispecific antibody-drug conjugate.
- Milestone Payment: The first dosing triggers a $5 million milestone payment to Biocytogen under their option and license agreement, providing financial support and indicating positive progress in their collaboration.
- Drug Characteristics: IDE034 targets tumor cells co-expressing B7H3 and PTK7, with an estimated 30-40% co-expression across several major solid tumors, highlighting its potential for selectivity and tolerability in cancer treatment.
- Future Development: IDEAYA plans to evaluate combination regimens of IDE034 with its oral PARG inhibitor IDE161 as the program advances, potentially offering new therapeutic options in oncology.
See More
IDEAYA Grants 346,200 Stock Options to New Employees
- Options Granted: On February 26, 2026, IDEAYA granted a total of 346,200 non-qualified stock options to three newly hired employees, aimed at attracting top talent to enhance the team’s capabilities in advancing precision medicine research.
- Incentive Plan Context: The stock options were granted under the Nasdaq Listing Rule 5635(c)(4) as part of the 2023 Employment Inducement Incentive Award Plan, specifically designed to incentivize individuals who were not previously employed by IDEAYA.
- Exercise Price Details: The options have an exercise price of $31.90 per share, which matches the closing price of IDEAYA's common stock on the Nasdaq Global Select Market on the grant date, aligning employee interests with those of shareholders.
- Vesting Schedule: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following three years, ensuring ongoing employee commitment during their tenure at IDEAYA.
See More
IDEAYA Grants 346,200 Stock Options to New Employees
- Options Granted: On February 26, 2026, IDEAYA Biosciences granted a total of 346,200 non-qualified stock options to three newly hired employees, aimed at attracting top talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Incentive Plan Context: The stock options were awarded under the 2023 Employment Inducement Incentive Award Plan, which is exclusively for granting equity awards to individuals who were not previously employed by IDEAYA, reflecting the company's commitment to new hires.
- Exercise Price Details: The options have an exercise price of $31.90 per share, matching the closing price of IDEAYA's common stock on the grant date on the Nasdaq Global Select Market, aligning employee incentives with company performance.
- Vesting Schedule: The stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments, ensuring ongoing employee contributions during their tenure at IDEAYA.
See More
IDEAYA Biosciences Initiates Phase 1 Trial for IDE034
- Trial Initiation: IDEAYA Biosciences has enrolled its first patient in the Phase 1 dose escalation/expansion trial for IDE034, marking a significant advancement in precision oncology, with plans to evaluate the drug's safety and tolerability.
- Milestone Payment Triggered: The dosing of the first patient will trigger a $5 million milestone payment from IDEAYA to Biocytogen, highlighting a critical milestone in their drug development collaboration and strengthening their partnership.
- Combination Therapy Potential: IDE034, a bispecific antibody-drug conjugate, is expected to enhance efficacy and tolerability when used in combination with IDE161, the company's proprietary PARG inhibitor, particularly in 30-40% of certain large solid tumor types where co-expression is observed.
- Innovative Drug Development: The design of IDE034 allows for internalization only when its target antigens are co-expressed on tumor cells, potentially providing a therapeutic advantage and further establishing IDEAYA's leadership in precision oncology.
See More
IDEAYA Initiates Phase 1 Trial for IDE034
- Trial Commencement: IDEAYA Biosciences has announced the enrollment of the first patient in its Phase 1 dose escalation trial for IDE034, aimed at evaluating the safety, tolerability, and pharmacokinetics, marking a significant advancement in the company's oncology drug development efforts.
- Milestone Payment Triggered: The dosing of the first patient will trigger a $5 million milestone payment from IDEAYA to Biocytogen, reflecting the collaborative relationship established under their Option and License Agreement, which further solidifies the company's strategic positioning in the biopharmaceutical sector.
- Combination Therapy Potential: IDE034, as a bispecific antibody-drug conjugate, is expected to enhance efficacy and tolerability when used in combination with the company's proprietary PARG inhibitor, IDE161, particularly showing promise across various solid tumors such as lung, breast, ovarian, and colorectal cancers.
- Market Positioning: Targeting tumor cells co-expressing B7H3/PTK7, which IDEAYA estimates to occur in approximately 30-40% of large tumor types, IDE034 may become the first treatment specifically designed for these antigens, potentially advancing the company's leadership in precision medicine.
See More
IDEAYA Initiates Phase 1 Trial for IDE892
- Trial Commencement: IDEAYA Biosciences has announced the enrollment of the first patient in its Phase 1 clinical trial for IDE892, a potential best-in-class PRMT5 inhibitor targeting MTAP-deleted solid tumors, highlighting the company's leadership in precision oncology.
- Drug Properties Advantage: IDE892 exhibits approximately 1,400-fold selective binding to MTA-PRMT5 complexes and demonstrates single-digit nanomolar potency in MTAP-deleted cell lines, indicating its potential to significantly enhance clinical outcomes for patients.
- Combination Therapy Potential: The combination with IDE397 has shown durable tumor regressions in preclinical models, suggesting that dual inhibition strategies may provide new treatment options for patients with MTAP-deleted tumors, addressing the urgent market need for effective therapies.
- Strategic Priority Shift: IDEAYA is deprioritizing clinical combination activities with Trodelvy to focus on advancing its MTAP-deleted pipeline, demonstrating the company's strong commitment to precision therapies and aiming to capture future market opportunities.
See More
Biocytogen and IDEAYA Advance New Drug Clinical Trial
- Trial Initiation: IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, aimed at evaluating the drug's safety, tolerability, and pharmacokinetics, marking a significant step in the clinical evaluation of this bispecific antibody-drug conjugate.
- Milestone Payment: The first dosing triggers a $5 million milestone payment to Biocytogen under their option and license agreement, providing financial support and indicating positive progress in their collaboration.
- Drug Characteristics: IDE034 targets tumor cells co-expressing B7H3 and PTK7, with an estimated 30-40% co-expression across several major solid tumors, highlighting its potential for selectivity and tolerability in cancer treatment.
- Future Development: IDEAYA plans to evaluate combination regimens of IDE034 with its oral PARG inhibitor IDE161 as the program advances, potentially offering new therapeutic options in oncology.
See More
IDEAYA Grants 346,200 Stock Options to New Employees
- Options Granted: On February 26, 2026, IDEAYA granted a total of 346,200 non-qualified stock options to three newly hired employees, aimed at attracting top talent to enhance the team’s capabilities in advancing precision medicine research.
- Incentive Plan Context: The stock options were granted under the Nasdaq Listing Rule 5635(c)(4) as part of the 2023 Employment Inducement Incentive Award Plan, specifically designed to incentivize individuals who were not previously employed by IDEAYA.
- Exercise Price Details: The options have an exercise price of $31.90 per share, which matches the closing price of IDEAYA's common stock on the Nasdaq Global Select Market on the grant date, aligning employee interests with those of shareholders.
- Vesting Schedule: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following three years, ensuring ongoing employee commitment during their tenure at IDEAYA.
See More
IDEAYA Grants 346,200 Stock Options to New Employees
- Options Granted: On February 26, 2026, IDEAYA Biosciences granted a total of 346,200 non-qualified stock options to three newly hired employees, aimed at attracting top talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Incentive Plan Context: The stock options were awarded under the 2023 Employment Inducement Incentive Award Plan, which is exclusively for granting equity awards to individuals who were not previously employed by IDEAYA, reflecting the company's commitment to new hires.
- Exercise Price Details: The options have an exercise price of $31.90 per share, matching the closing price of IDEAYA's common stock on the grant date on the Nasdaq Global Select Market, aligning employee incentives with company performance.
- Vesting Schedule: The stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments, ensuring ongoing employee contributions during their tenure at IDEAYA.
See More
IDEAYA Biosciences Initiates Phase 1 Trial for IDE034
- Trial Initiation: IDEAYA Biosciences has enrolled its first patient in the Phase 1 dose escalation/expansion trial for IDE034, marking a significant advancement in precision oncology, with plans to evaluate the drug's safety and tolerability.
- Milestone Payment Triggered: The dosing of the first patient will trigger a $5 million milestone payment from IDEAYA to Biocytogen, highlighting a critical milestone in their drug development collaboration and strengthening their partnership.
- Combination Therapy Potential: IDE034, a bispecific antibody-drug conjugate, is expected to enhance efficacy and tolerability when used in combination with IDE161, the company's proprietary PARG inhibitor, particularly in 30-40% of certain large solid tumor types where co-expression is observed.
- Innovative Drug Development: The design of IDE034 allows for internalization only when its target antigens are co-expressed on tumor cells, potentially providing a therapeutic advantage and further establishing IDEAYA's leadership in precision oncology.
See More
IDEAYA Initiates Phase 1 Trial for IDE034
- Trial Commencement: IDEAYA Biosciences has announced the enrollment of the first patient in its Phase 1 dose escalation trial for IDE034, aimed at evaluating the safety, tolerability, and pharmacokinetics, marking a significant advancement in the company's oncology drug development efforts.
- Milestone Payment Triggered: The dosing of the first patient will trigger a $5 million milestone payment from IDEAYA to Biocytogen, reflecting the collaborative relationship established under their Option and License Agreement, which further solidifies the company's strategic positioning in the biopharmaceutical sector.
- Combination Therapy Potential: IDE034, as a bispecific antibody-drug conjugate, is expected to enhance efficacy and tolerability when used in combination with the company's proprietary PARG inhibitor, IDE161, particularly showing promise across various solid tumors such as lung, breast, ovarian, and colorectal cancers.
- Market Positioning: Targeting tumor cells co-expressing B7H3/PTK7, which IDEAYA estimates to occur in approximately 30-40% of large tumor types, IDE034 may become the first treatment specifically designed for these antigens, potentially advancing the company's leadership in precision medicine.
See More
